Chronic Lower Back Pain - Pipeline Insight, 2024

Chronic Lower Back Pain - Pipeline Insight, 2024

DelveInsight’s, “Chronic Lower Back Pain - Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Chronic Lower Back Pain pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Chronic Lower Back Pain Understanding

Chronic Lower Back Pain: Overview

Low back pain that has been present for longer than three months is considered as chronic, although there is still no consensus about the definition of Chronic Lower Back Pain (CLBP). 5-10% of all low back pain patients will develop CLBP. Chronic low back pain (CLBP) has been associated with neurochemical, structural, and functional cortical changes of several brain regions including the somatosensory cortex. Complex processes of peripheral and central sensitization may influence the evolution of acute to chronic pain. Most patients that suffer from CLBP experience pain in the lower area of the back (lumbar and sacroiliac regions) and mobility impairment. Diagnosis of low back pain is done on the basis of physical examination and patient history, sometimes followed by x-rays, CT scan, MRI, or other medical tests. Treatment for CLBP includes medications like acetaminophen (Tylenol), ibuprofen (Advil), and naproxen (Aleve). Physical therapy, occupational therapy, and lifestyle modification as well as other forms of exercise are also helpful.

""Chronic Lower Back Pain - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic Lower Back Pain pipeline landscape is provided which includes the disease overview and Chronic Lower Back Pain treatment guidelines. The assessment part of the report embraces, in depth Chronic Lower Back Pain commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Lower Back Pain collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Lower Back Pain R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Lower Back Pain.

Chronic Lower Back Pain Emerging Drugs Chapters

This segment of the Chronic Lower Back Pain report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chronic Lower Back Pain Emerging Drugs

• MPC-06-ID: Mesoblast

MPC-06-ID is a tier 1 product candidate which consists of a unit dose of 6 million mesenchymal precursor cells (MPCs). It is injected by syringe directly into a targeted damaged disc in an outpatient procedure. MPC-06-ID is a Phase III product candidate for the treatment of chronic low back pain caused by disc degeneration (CLBP). It is being developed for patients who have exhausted conservative treatment options, may have failed epidural steroid injections and have no further treatment option other than invasive and costly surgical interventions.

• PP353: Persica Pharmaceuticals

PP353 is a unique combination of an antibiotic, a radio-opaque dye and a thermosensitive gel that provides a product for intradiscal injection. It is currently being studied in Phase I/II developmental studies for the treatment of patients with Chronic Low Back Pain associated with verterbral body endplate bone oedema.

Further product details are provided in the report……..

Chronic Lower Back Pain: Therapeutic Assessment

This segment of the report provides insights about the different Chronic Lower Back Pain drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Chronic Lower Back Pain

There are approx. 10+ key companies which are developing the therapies for Chronic Lower Back Pain. The companies which have their Chronic Lower Back Pain drug candidates in the most advanced stage, i.e. Phase III include, Mesoblast.

• Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Chronic Lower Back Pain pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Chronic Lower Back Pain: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Chronic Lower Back Pain therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic Lower Back Pain drugs.

Chronic Lower Back Pain Report Insights

• Chronic Lower Back Pain Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Chronic Lower Back Pain Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Chronic Lower Back Pain drugs?
• How many Chronic Lower Back Pain drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Lower Back Pain?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chronic Lower Back Pain therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Chronic Lower Back Pain and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Mesoblast
• Eli Lilly and Company
• Persica Pharmaceuticals
• CHABiotech
• Allodynic Therapeutics
• Stayble Therapeutics
• Xgene Pharmaceutical
• Imbrium Therapeutics
• Camurus

Key Products

• MPC-06-ID
• LY3016859
• PP353
• CordSTEM-DD
• ALLOD 2
• STA 363
• XG005
• SX600
• CAM2038